212 related articles for article (PubMed ID: 11729387)
41. I-124 Imaging and Dosimetry.
Kuker R; Sztejnberg M; Gulec S
Mol Imaging Radionucl Ther; 2017 Feb; 26(Suppl 1):66-73. PubMed ID: 28117290
[TBL] [Abstract][Full Text] [Related]
42. Surgical decision making in the management of well-differentiated thyroid cancer.
Chernichenko N; Shaha AR
Indian J Surg Oncol; 2012 Sep; 3(3):161-5. PubMed ID: 23997503
[TBL] [Abstract][Full Text] [Related]
43. Diagnostic and Therapeutic Radiopharmaceuticals: A "Hot" Topic.
Lindsley CW; Müller CE; Bongarzone S
ACS Pharmacol Transl Sci; 2024 Jan; 7(1):1-7. PubMed ID: 38230278
[No Abstract] [Full Text] [Related]
44. Importance of ELABELA in the differential diagnosis of benign and malignant lesions of the thyroid gland.
Bankir M; Abayli C; Acibucu F
Arch Endocrinol Metab; 2021 Nov; 64(6):772-778. PubMed ID: 33049129
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of
Lee DW; Song CM; Ji YB; Kim JY; Choi YY; Lee JY; Tae K
OTO Open; 2018; 2(3):2473974X18788545. PubMed ID: 31535061
[TBL] [Abstract][Full Text] [Related]
46. Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis.
Schütz F; Lautenschläger C; Lorenz K; Haerting J
Eur Thyroid J; 2018 Jan; 7(1):13-20. PubMed ID: 29594049
[TBL] [Abstract][Full Text] [Related]
47. Metabolic Alterations of Thyroid Cancer as Potential Therapeutic Targets.
Ciavardelli D; Bellomo M; Consalvo A; Crescimanno C; Vella V
Biomed Res Int; 2017; 2017():2545031. PubMed ID: 29234677
[TBL] [Abstract][Full Text] [Related]
48. F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis.
Haslerud T; Brauckhoff K; Reisæter L; Küfner Lein R; Heinecke A; Varhaug JE; Biermann M
Acta Radiol; 2016 Oct; 57(10):1193-200. PubMed ID: 26163534
[TBL] [Abstract][Full Text] [Related]
49. Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET (THYROPET Study): study protocol of a multicenter observational cohort study.
Kist JW; de Keizer B; Stokkel MP; Hoekstra OS; Vogel WV;
BMC Cancer; 2014 Jun; 14():405. PubMed ID: 24906384
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic impact of (18)F-FDG PET/CT in recurrent differentiated thyroid carcinoma.
Pomerri F; Cervino AR; Al Bunni F; Evangelista L; Muzzio PC
Radiol Med; 2014 Feb; 119(2):97-102. PubMed ID: 24277507
[TBL] [Abstract][Full Text] [Related]
51. German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.
Dralle H; Musholt TJ; Schabram J; Steinmüller T; Frilling A; Simon D; Goretzki PE; Niederle B; Scheuba C; Clerici T; Hermann M; Kußmann J; Lorenz K; Nies C; Schabram P; Trupka A; Zielke A; Karges W; Luster M; Schmid KW; Vordermark D; Schmoll HJ; Mühlenberg R; Schober O; Rimmele H; Machens A;
Langenbecks Arch Surg; 2013 Mar; 398(3):347-75. PubMed ID: 23456424
[TBL] [Abstract][Full Text] [Related]
52. Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management.
Schreinemakers JM; Vriens MR; Munoz-Perez N; Guerrero MA; Suh I; Rinkes IH; Gosnell J; Shen WT; Clark OH; Duh QY
World J Surg Oncol; 2012 Sep; 10():192. PubMed ID: 22985118
[TBL] [Abstract][Full Text] [Related]
53. The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Prognostication, Diagnosis, and Management of Thyroid Carcinoma.
Lang BH
J Thyroid Res; 2012; 2012():198313. PubMed ID: 22007340
[TBL] [Abstract][Full Text] [Related]
54. Role of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative ¹³¹I scan: review of the literature.
Bertagna F; Biasiotto G; Orlando E; Bosio G; Giubbini R
Jpn J Radiol; 2010 Nov; 28(9):629-36. PubMed ID: 21113746
[TBL] [Abstract][Full Text] [Related]
55. The accuracy of (18)[F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography, ultrasonography, and enhanced computed tomography alone in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma.
Morita S; Mizoguchi K; Suzuki M; Iizuka K
World J Surg; 2010 Nov; 34(11):2564-9. PubMed ID: 20645089
[TBL] [Abstract][Full Text] [Related]
56. Role and cost effectiveness of PET/CT in management of patients with cancer.
Saif MW; Tzannou I; Makrilia N; Syrigos K
Yale J Biol Med; 2010 Jun; 83(2):53-65. PubMed ID: 20589185
[TBL] [Abstract][Full Text] [Related]
57. Clinical and imaging assessment of cervical lymph node metastasis in papillary thyroid carcinomas.
Choi YJ; Yun JS; Kook SH; Jung EC; Park YL
World J Surg; 2010 Jul; 34(7):1494-9. PubMed ID: 20372903
[TBL] [Abstract][Full Text] [Related]
58. The value of positron emission tomography in the surgical management of recurrent papillary thyroid carcinoma.
Grant CS; Thompson GB; Farley DR; Richards ML; Mullan BP; Hay ID
World J Surg; 2008 May; 32(5):708-15. PubMed ID: 18204948
[TBL] [Abstract][Full Text] [Related]
59. Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence.
Curtet C; Carlier T; Mirallié E; Bodet-Milin C; Rousseau C; Barbet J; Kraeber-Bodéré F
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1556-62. PubMed ID: 17522858
[TBL] [Abstract][Full Text] [Related]
60. Oncologic positron emission tomography: a surgical perspective.
Moore TO; Griffeth LK
Proc (Bayl Univ Med Cent); 2003 Jan; 16(1):13-20. PubMed ID: 16278717
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
